What is Esperite?
Founded in 2000 and formerly known as Cryo-Save Group N.V., Esperite N.V. has evolved into a multifaceted healthcare entity. The company operates through four distinct segments: Stem Cell, The Cell Factory, Genoma, and Other. Its core competencies lie in the collection, processing, and storage of human adult stem cells, alongside the development of advanced diagnostic systems such as AGAATA. By integrating next-generation sequencing technology with bioinformatics, Esperite provides essential tools for genetic analysis and prenatal testing, including the Tranquility non-invasive prenatal test. The company's transition from a traditional biobanking firm to a comprehensive predictive medicine provider highlights its strategic pivot toward high-margin, technology-driven healthcare solutions.
How much funding has Esperite raised?
Esperite has raised a total of $41M across 1 funding round:
Share Placement
$41M
Share Placement (2020): $41M, investors not publicly disclosed
Key Investors in Esperite
Undisclosed Investor
An undisclosed institutional investor participating in the funding round, focusing on long-term growth in the biotechnology and life sciences sectors.
Undisclosed Investor
A strategic partner providing capital to support the scaling of clinical-grade stem cell production and diagnostic technology development.
Undisclosed Investor
An investment entity specializing in the advancement of predictive medicine and genomic research infrastructure.
What's next for Esperite?
Looking ahead, Esperite is poised to leverage its recent capital infusion to enhance its clinical-grade production of autologous mesenchymal and stromal stem cells. The strategic roadmap focuses on deepening the integration of its Genoma segment's bioinformatics capabilities with its existing biobanking infrastructure. As the demand for personalized, data-backed medical interventions continues to rise, Esperite's commitment to innovation in whole genome sequencing and carrier screening positions it to capture significant market share. The company will likely prioritize operational efficiency and the expansion of its diagnostic product portfolio to maintain its trajectory as a leader in the European regenerative medicine landscape.
See full Esperite company page
